Real-world evidence: the devil is in the detail

被引:49
作者
Gokhale, Mugdha [1 ,2 ]
Sturmer, Til [2 ]
Buse, John B. [3 ]
机构
[1] Merck, Pharmacoepidemiol, Ctr Observat & Real World Evidence, 770 Sumneytown Pike, West Point, PA 19486 USA
[2] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
[3] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金
美国国家卫生研究院;
关键词
Active comparator; Bias; Data; Evidence; Healthcare; New-user; Pharmacoepidemiology; Real-world; Review; Study design; DISEASE RISK SCORES; ELECTRONIC HEALTH RECORDS; PROPENSITY SCORES; INSTRUMENTAL VARIABLES; CAUSAL INFERENCE; USER DESIGN; CLAIMS DATA; TASK-FORCE; CANCER; MORTALITY;
D O I
10.1007/s00125-020-05217-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Much has been written about real-world evidence (RWE), a concept that offers an understanding of the effects of healthcare interventions using routine clinical data. The reflection of diverse real-world practices is a double-edged sword that makes RWE attractive but also opens doors to several biases that need to be minimised both in the design and analytical phases of non-experimental studies. Additionally, it is critical to ensure that researchers who conduct these studies possess adequate methodological expertise and ability to accurately implement these methods. Critical design elements to be considered should include a clearly defined research question using a causal inference framework, choice of a fit-for-purpose data source, inclusion of new users of a treatment with comparators that are as similar as possible to that group, accurately classifying person-time and deciding censoring approaches. Having taken measures to minimise bias 'by design', the next step is to implement appropriate analytical techniques (for example propensity scores) to minimise the remnant potential biases. A clear protocol should be provided at the beginning of the study and a report of the results after, including caveats to consider. We also point the readers to readings on some novel analytical methods as well as newer areas of application of RWE. While there is no one-size-fits-all solution to evaluating RWE studies, we have focused our discussion on key methods and issues commonly encountered in comparative observational cohort studies with the hope that readers are better equipped to evaluate non-experimental studies that they encounter in the future.
引用
收藏
页码:1694 / 1705
页数:12
相关论文
共 99 条
[1]  
Agency for Healthcare Research and Quality, 2012, INC US DES COMP EFF
[2]  
Allie Nawrat Pharma Technology Focus, 2019, REAL WORLD DAT HOW C
[3]   Guidelines for good pharmacoepidemiology practice (GPP) [J].
Andrews, Elizabeth B. ;
Arellano, Felix M. ;
Avorn, Jerry ;
Bortnichak, Edward A. ;
Chen, Robert ;
Dai, Wanju S. ;
de Abajo, Francisco J. ;
Dieck, Gretchen S. ;
de Vries, Corinne ;
Edlavitch, Stanley ;
Freiman, Joel ;
Hallas, Jesper ;
Jones, Judith K. ;
Koo, Linda ;
Kaufman, David W. ;
Kurz, Xavier ;
Lanes, Stephan ;
Mitchell, Allen A. ;
Moride, Yola ;
Nelson, Robert C. ;
Neutel, Ineke ;
Park, Byung-Joo ;
Perez-Gutthann, Susana ;
Reynolds, Robert ;
Sacks, Susan ;
Santanello, Nancy ;
Stang, Paul ;
Stergachis, Andrew ;
Strom, Brian L. ;
Stuermer, Til ;
Toh, Darren ;
Trontell, Anne ;
Walker, Alexander M. ;
Waller, Patrick ;
Watson, Douglas J. ;
West, Suzanne ;
Wilcock, Karen ;
Wise, Robert P. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (01) :2-10
[4]   Use of disease risk scores in pharmacoepidemiologic studies [J].
Arbogast, Patrick G. ;
Ray, Wayne A. .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2009, 18 (01) :67-80
[5]   Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Daniel Mullins, C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) :1033-1039
[6]   What is Machine Learning? A Primer for the Epidemiologist [J].
Bi, Qifang ;
Goodman, Katherine E. ;
Kaminsky, Joshua ;
Lessler, Justin .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2019, 188 (12) :2222-2239
[7]  
Blais L, 1996, AM J EPIDEMIOL, V144, P1161
[8]   Reflection on modern methods: when worlds collide-prediction, machine learning and causal inference [J].
Blakely, Tony ;
Lynch, John ;
Simons, Koen ;
Bentley, Rebecca ;
Rose, Sherri .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2020, 49 (06) :2058-2064
[9]   Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].
Bowker, SL ;
Majumdar, SR ;
Veugelers, P ;
Johnson, JA .
DIABETES CARE, 2006, 29 (02) :254-258
[10]   Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins [J].
Bradley, Marie C. ;
Chillarige, Yoganand ;
Lee, Hana ;
Wu, Xiyuan ;
Parulekar, Shruti ;
Wernecke, Michael ;
Bright, Patricia ;
Soukup, Mat ;
MaCurdy, Thomas E. ;
Kelman, Jeffrey A. ;
Graham, David J. .
DIABETES CARE, 2020, 43 (04) :785-792